Comprehensive investigation of CPSF3's role in the progression of bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a ...
A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory ...
86% of patients on 400+ mg of INCA033989 had a complete or partial hematologic response. 89% of patients showed a reduction in mutCALR VAF, with 21% achieving >50% drop in just three cycles. A new ...
In this exclusive MedPage Today video, Virginia Kaklamani, MD, DSc, of UT Health Sciences Center in San Antonio and co-director of the San Antonio Breast Cancer Symposium (SABCS), discusses a subgroup ...
Promising Biomarker Reductions: Treatment with the MDM2 inhibitor navtemadlin led to significant reductions in key biomarkers of disease severity, including circulating CD34+ cells, a hallmark of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results